By Michael Gwarisa The Zvandiri model, a peer-led program focused on children, adolescents, and young adults living with HIV aged 0-24, was launched in Zimbabwe 2o years ago mainly as a vehicle to increase and improve access to treatment and care for children and young persons living with HIV. The model Zvandiri is implemented by
Read MoreBy Michael Gwarisa Thirteen African countries are in Zimbabwe for a three-day consultation meeting to deliberate on the progress and gaps in the scaled-up Zvandiri peer provider model toward ending AIDS in children and adolescents. Zvandiri is implementing the Zvandiri model in Zimbabwe in partnership with the Ministry of Health and Child Care (MOHCC). The
Read MoreBy Staff Reporter Lima, Peru – The Population Council, an international nonprofit research organization, announced today at HIVR4P 2024, the 5th HIV Research for Prevention Conference, the results of a phase I open-label randomized crossover relative bioavailability trial (IPM 054). The trial found that a 3-month dapivirine vaginal ring delivers the active antiretroviral drug, dapivirine,
Read MoreBy Kuda Pembere With Zimbabwe being among the 18 top-priority recipients of lenacapavir an HIV preventive drug pending local medicines regulatory approvals, Gilead Sciences, the principal maker has granted a non-exclusive license to leading India headquartered pharmaceutical manufacturer Hetero Group of Companies to manufacture and supply the drug. Gilead’s decision comes following much advocacy by
Read MoreBy Kuda Pembere in Mvurwi Several interventions have been credited to the reduction of HIV prevalence in Mashonaland Central with the province now ranking the fifth highest in the country. Despite Mazowe topping the list in the past two years, due to some targeted interventions, it has now been overtaken by Bindura where the Provincial
Read MoreBy Takunda Mandura Having been diagnosed with HIV during her first pregnancy 15 years ago, Moud Chinembiri, now a mother of two children, has defied the odds and looked the beast in the eye. Now her child whom she had when she had a positive HIV diagnosis is attending high school and is HIV-negative, a
Read MoreBy Michael Gwarisa While Zimbabwe has made significant strides in addressing the HIV burden, there is a need for renewed messaging regarding HIV prevention to sustain the gains realised, health experts have said. Zimbabwe is among the few African countries that have attained the UNIADS 95-9-95 targets in adults. Over the past four years, there
Read MoreBy Michael Gwarisa A new Global Parliamentary Platform on HIV and AIDS has been established at the ongoing International AIDS Conference in Munich, Germany in a bid to build momentum to end AIDS ahead of the 2030 target. The new platform is set to provide the space, tools, and other resources to unite, strengthen, and
Read MoreGilead could bring the AIDS pandemic towards an end if the US pharmaceutical giant opens up access to its game-changing new HIV drug, the head of UNAIDS told AFP. Winnie Byanyima urged Gilead to “make history” by allowing generic manufacturing of Lenacapavir, a twice-yearly injectable antiretroviral medication used to treat HIV patients. She urged Gilead to open
Read MoreThe results of the PrEPVacc HIV vaccine trial conducted in Eastern and Southern Africa, which ran between 2020 and 2024, show conclusively that neither of the two experimental vaccine regimens tested reduced HIV infections among the study population. Vaccinations in the PrEPVacc trial were stopped in November 2023 (and publicly announced in December 2023) when
Read More